Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H33F2N5O4S.ClH |
Molecular Weight | 634.137 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(=O)NC1=C(C=CC=C1C2=CC=CC=C2)S(=O)(=O)N[C@@H](CCCC3=NC=C(N)C=C3)C(=O)N4CCC(CC4)=C(F)F
InChI
InChIKey=JOWCHVSUAJPEIA-SNYZSRNZSA-N
InChI=1S/C30H33F2N5O4S.ClH/c1-20(38)35-28-25(21-7-3-2-4-8-21)10-6-12-27(28)42(40,41)36-26(11-5-9-24-14-13-23(33)19-34-24)30(39)37-17-15-22(16-18-37)29(31)32;/h2-4,6-8,10,12-14,19,26,36H,5,9,11,15-18,33H2,1H3,(H,35,38);1H/t26-;/m0./s1
Molecular Formula | C30H33F2N5O4S |
Molecular Weight | 597.676 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:59:49 GMT 2023
by
admin
on
Sat Dec 16 02:59:49 GMT 2023
|
Record UNII |
TJU7LB4AF2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TJU7LB4AF2
Created by
admin on Sat Dec 16 02:59:49 GMT 2023 , Edited by admin on Sat Dec 16 02:59:49 GMT 2023
|
PRIMARY | |||
|
69820681
Created by
admin on Sat Dec 16 02:59:49 GMT 2023 , Edited by admin on Sat Dec 16 02:59:49 GMT 2023
|
PRIMARY | |||
|
362615-85-8
Created by
admin on Sat Dec 16 02:59:49 GMT 2023 , Edited by admin on Sat Dec 16 02:59:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antithrombotic; Mechanism of Action: Thrombin inhibitor; Highest Development Phase: Discontinued for Thrombosis; Most Recent Event: 23 Mar 2009 Discontinued - Phase-II for Thrombosis in Europe (PO)
|
||
|
ACTIVE MOIETY |
The compound is a potent inhibitor of thrombin's activities in vitro and demonstrates potent oral anti-thrombotic potencies in three rat models of thrombosis. The observed in vitro potency could be rationalized through the examination of the interactions within the SSR182289A 1 - thrombin crystal structure. SSR182289A 1, has been therefore selected for further development.
|
||
|
ACTIVE MOIETY |
SSR182289A competitively inhibits human thrombin (K(i) = 0.031 +/- 0.002 microM) and shows good selectivity with respect to other human proteases, e.g., trypsin (K(i) = 54 +/- 2 microM), factor Xa (K(i) = 167 +/- 9 microM), and factor VIIa, factor IXa, plasmin, urokinase, tPA, kallikrein, and activated protein C (all K(i) values >250 microM). In human plasma, SSR182289A demonstrated anticoagulant activity in vitro as measured by standard clotting parameters (EC100 thrombin time 96 +/- 7 nM) and inhibited tissue factor-induced thrombin generation (IC50 of 0.15 +/- 0.02 microM). Hence, SSR182289A is a potent, selective, and orally active thrombin inhibitor.
|